Guoqian Venture Capital

Guoqian Venture Capital focuses on the equity investment in the early and middle stage of start-ups in the medical devices, which is an important step to implement the strategic roadmap “Industry + Capital”.

Chen Hao

Partner

9 past transactions

Bioantibody

Series A in 2023
Bioantibody is a high-tech biotechnology firm specializing in the research and development of antigens, antibodies, and downstream detection reagents for diagnosis and therapy.

Baikang Bio

Series A in 2023
Baikang Bio is a tech biotechnology firm specializing in the research and development of antigens, antibodies, and downstream detection reagents for diagnosis and therapy. The product pipelines cover cardiovascular and cerebrovascular, inflammation, infectious diseases, tumors, hormones, and other categories, from raw materials to finished goods. They are dedicated to innovation and providing their customers with solutions. They could contribute to human ecology and health.

Nenstar Electronic Technology

Venture Round in 2022
Leanstar Sensor has developed the core design capabilities of multi-variety and multi-range flexible micro-nano mechanical force sensors. Their products are flexible pressure sensors, flexible piezoelectric sensors, flexible capacitive sensors, flexible thermal sensors, flexible temperature and humidity sensors, and flexible integrated composite micro-nano sensors.

MagAssist

Series B in 2021
Suzhou Xinqing Medical Technology Co., Ltd. was founded in 2017 by Dr. Xu Bozhen, a special expert of the National Youth Thousand People Program and a special professor of Suzhou University. He is a high-tech enterprise with the main goal of developing the world's leading in vitro short-term ventricular assist device (in vitro artificial heart). . The core members of the company's entrepreneurial team are the world's top artificial heart engineering technology experts. With years of experience in overseas artificial heart research and development and productization, the company has developed a domestically produced artificial heart with independent intellectual property rights.

Dima Biotech

Angel Round in 2019
Dima Biotech is a tumor immunotherapy and monoclonal antibody developer, specializing in the development of recombinant monoclonal antibodies for tumor immune products and services. It has the unique RECmAb digital monoclonal antibody technology, which can be used to obtain a variety of genus and high quality. Monoclonal antibodies.

MagAssist

Series A in 2019
Suzhou Xinqing Medical Technology Co., Ltd. was founded in 2017 by Dr. Xu Bozhen, a special expert of the National Youth Thousand People Program and a special professor of Suzhou University. He is a high-tech enterprise with the main goal of developing the world's leading in vitro short-term ventricular assist device (in vitro artificial heart). . The core members of the company's entrepreneurial team are the world's top artificial heart engineering technology experts. With years of experience in overseas artificial heart research and development and productization, the company has developed a domestically produced artificial heart with independent intellectual property rights.

Guoke Junhao

Seed Round in 2019
Guoke Junhao is a POCT medical device and diagnostic reagent research and development distributor, focusing on the field of chemiluminescence immunoassay, mainly developing small automatic microfluidic immunoassay analyzer, which can realize inspection automation, fast and efficient, low cost, simple operation, etc.

EYESEE

Angel Round in 2017
EYESEE offers ophthalmology chain clinics, vision screening, behavioral awareness education, and big data platform construction services. They give a myopia prevention and control strategy, one plan for one person, and one countermeasure for one person. They entered the campus, established eye health records, and cleverly forecasted the presence and progression of myopia in children and adolescents. They also created an artificial intelligence system for visual acuity screening.

APOLLOMICS

Angel Round in 2015
APOLLOMICS is a biotechnology company that develops domestic clinical testing reagents and provides disease testing services.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.